AtriCure Inc. disclosed today the Mason-based medical device maker could pay up to $300 million to acquire a California firm that also makes devices to treat heart ailments.
An upfront payment of about $40 million in cash and AtriCure common stock (Nasdaq: ATRC) will be made to SentreHeart Inc., a privately held developer of percutaneous left atrial appendage management solutions.
Another $140 million is contingent on milestones related to SentreHeart’s aMaze IDE clinical trial, including FDA premarket approval, and $120 million is based on a milestone related to reimbursement for the therapy involving SentreHeart devices.
Click here to read the complete article.
Story excerpt provided by Dayton Business Journal.
Written by Barrett J. Brunsman.
Originally published August 13, 2019.